For the full story, please visit:
In late January, a community health center began offering an outpatient infusion clinic for administering an antibody treatment called BAM that is looked at as a means to give hope to those infected with the virus, especially as vaccine rollout is still taking time…
This year has posed some new challenges in the medical industry with immunocompromised patients concerned about their health due to Covid-19. Independent infusion service providers empower these at-risk patients to administer their medication in the home setting or at an infusion center.
COVID-19 infusion treatments were authorized by the Food and Drug Administration for emergency use against COVID-19 back in November to impede disease progression and prevent hospitalization for patients.
These highlights do not include all the information needed to use Octagam 10% safely and effectively. See full prescribing information for Octagam 10%.
Prospective, double-blind, randomized, placebocontrolled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)
ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System
